Semaglutide May Cut Cardiovascular Risk Before Weight Loss
In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or full dosing was achieved. Medscape Medical News
Month: May 2025
Incretin mimetics for weight loss forgive nonadherence
Abstract Aims GLP-1 and GIP-GLP-1 agonists have emerged as potent weight-loss medications. These incretin mimetics often have low patient adherence, and as with any medication, clinically meaningful efficacy requires adequate adherence. But what constitutes “adequate” adherence for incretin mimetics? The purpose of this paper is to address this question. Materials and Methods We use mathematical … Read more
First-Generation GLP-1 Drugs May Help Lower Risk of Obesity-Related Cancers
A new study shows GLP-1 drugs liraglutide, exenatide, and dulaglutide were 41% more effective at preventing obesity-related cancers. Carsten Snejbjerg/Bloomberg via Getty Images First-generation GLP-1 weight-loss drugs could help reduce the risk of obesity-related cancers, new research shows. These medications have been around longer than the newer, better-known GLP-1 drugs, such as Ozempic, but they … Read more
Trump targets high drug prices as GLP-1 medications reshape obesity treatment
Former FDA Commissioner Dr. David Kessler and Dr. Jon LaPook join CBS Mornings to discuss the science behind weight loss drugs and the president’s new plan to lower prescription costs.
Nestlé To Sell Perrier and All Other Water Brands
Nestlé has announced that it intends to sell Perrier and all its other water brands. Reuters is reporting that the retail giant has commissioned the Rothschild bank to sell off its entire water division, as the company looks to “refocus” on other brands. “Under new CEO Laurent Freixe, Nestlé has been trying to narrow its … Read more
Is the Fed on the Right Track?
In this podcast, Motley Fool host Dylan Lewis and analysts Tim Beyers and Bill Mann discuss: The Fed’s continued wait-and-see approach to tariff policy, inflation, and interest rate cuts. Ford‘s warning of tariff impacts. Why MercadoLibre is worth a look amid macro uncertainty. How Uber and DoorDash are both flourishing as they cash in on … Read more
Quantifying Benefits and Risks of GLP-1–Receptor Agonists for Patients with Diabetes
In a large data analysis, GLP-1 agonists lowered risk for many diseases that are not related to diabetes.
GLP-1 drugs made a former FDA chief ‘feel ill.’ But he’d take them again.
David Kessler has lost more than 60 pounds on weight-loss drugs and believes they can change the trajectory of chronic disease in the United States.
Weight loss drugs have “no end game,” former FDA commissioner warns
Former FDA Commissioner David Kessler shared his experience with GLP-1 weight loss drugs on “CBS Mornings Plus.”
Trump Calls Out Weight-loss Drugs as Target Of Price-cut Push
The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its push to lower prescription drug… Reuters Health Information